Ultimately, the interplay between AURKA and the PD-L1/PD-1 signaling axis appears to be complex and highly context-dependent, underscoring the importance of studying these relationships in diverse preclinical models and clinical settings to fully understand the therapeutic implications and potential for targeting these pathways in cancer treatment. This evidence concerns the gene PDCD1 and cancer.